4D Advisors Offloads $7.6 Million in Masimo (MASI) Stock, Selling 45,000 Shares

On Nov. 14, 2025, 4D Advisors, LLC disclosed in a regulatory filing that it sold out its entire position in Masimo (NASDAQ:MASI). The sale was valued at $7.57 million.

What happened

According to a filing with the Securities and Exchange Commission dated November 14, 2025, 4D Advisors, LLC reported selling its entire stake in Masimo. The fund exited by selling 45,000 shares, with the transaction value being approximately $7,569,900, based on average pricing during the quarter. The firm held 0 shares of Masimo at the end of the third quarter of 2025.

What else to know

• This was a full sale; Masimo now represents 0% of the fund's reported 13F AUM
• Top holdings after the filing:
  • NASDAQ: APEI: $10,459,550 (5.5685% of AUM)
  • NYSE: TPB: $9,886,000 (5.2632% of AUM)
  • NYSE: USPH: $9,344,500 (4.9749% of AUM)
  • NYSE: SGHC: $9,240,000 (4.9193% of AUM)
  • NYSE: ONTO: $9,045,400 (4.8157% of AUM)
• As of November 14, 2025, shares were priced at $151.12, down 5.64% over the past year
• Stock underperformed the S&P 500 by 19.04 percentage points over the past 12 months
• The position was previously 4.0699% of fund AUM as of the prior quarter

Company Overview

Company Snapshot

• Massimo develops and markets noninvasive patient monitoring technologies, including pulse oximetry, brain function monitoring, capnography, and hospital automation solutions.
• Generates revenue through direct sales, distributors, and OEM partnerships targeting hospitals, emergency medical services, home care providers, and consumer channels.
• Primary customers include hospitals, healthcare providers, long-term care facilities, physician offices, veterinarians, and consumers worldwide.

Masimo is a global leader in advanced noninvasive patient monitoring and hospital automation technologies, serving the healthcare sector with a broad portfolio of critical care solutions. The company leverages proprietary signal extraction technology and integrated platforms to address key clinical needs and improve patient outcomes. Its diversified product suite and multi-channel distribution strategy provide a competitive edge in both professional and consumer health markets.

Foolish take

Masimo was the largest of 14 positions that 4D Advisors dispatched in the third quarter. It was a poor performer that fell by 12.3% during the three months ended Sep. 30, 2025. There are no longer any companies associated with medical device manufacturing in the portfolio's 10 largest holdings.

Masimo's smartwatch business has been disappointing, but its core healthcare segment is performing well. The company reported sales that grew by 8% year over year during the third quarter. For the full year, management expects sales to rise by 8.5% to 10%, excluding the effects of fluctuating currency exchange rates.

Massimo's foray into the consumer electronics business took a step back during the third quarter. The company sold its Sound United business to Harman and used the proceeds to repurchase its stock.

Instead of consumer electronics, Masimo expanded its partnership with Royal Philips (NYSE:PHG). Philips is a leading producer of medical devices that employ Masimo's pulse oximetry technology.

Glossary

13F reportable assets under management (AUM): The total value of securities a fund must report quarterly to the SEC.
Full exit: When an investor sells all shares of a particular holding, reducing its position to zero.
Quarterly average pricing: The average price of a security over a specific quarter, often used to estimate transaction values.
Stake: The amount of ownership or shares held in a company by an investor or fund.
OEM partnerships: Agreements where a company supplies components or products to another company, which then sells them under its own brand.
Capnography: The monitoring and measurement of carbon dioxide levels in exhaled breath, used in medical settings.
Signal extraction technology: Advanced methods for isolating useful data from complex or noisy signals, often used in medical devices.
TTM: The 12-month period ending with the most recent quarterly report.
Distribution strategy: The plan a company uses to deliver products to customers through various sales channels.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Masimo. The Motley Fool recommends Turning Point Brands. The Motley Fool has a disclosure policy.